10-QPeriod: Q1 FY2020

Elevance Health, Inc. Quarterly Report for Q1 Ended Mar 31, 2020

Filed April 29, 2020For Securities:ELV

Summary

Elevance Health, Inc. (formerly Anthem, Inc.) reported its first-quarter 2020 financial results, showing resilience despite the emerging COVID-19 pandemic. Total operating revenue increased by 20.7% to $29.4 billion, largely driven by the launch of its Pharmacy Benefit Manager (PBM) subsidiary, IngenioRx, and higher premium revenues from rate increases and membership growth in its Government Business segment. Net income saw a slight decrease of 1.8% to $1.5 billion, or $5.94 per diluted share, impacted by higher income tax expense due to the reinstatement of the Health Insurance Provider (HIP) Fee and net realized losses on financial instruments. The company completed the acquisition of Beacon Health Options, Inc., a significant move to diversify into behavioral health services. While facing economic uncertainties and potential impacts from COVID-19 on healthcare costs and membership, Elevance Health demonstrated strong operating cash flow growth and maintained a robust financial position. The company also highlighted its proactive measures to support members and employees during the pandemic, including waiving cost-sharing for telehealth and COVID-19 treatments, and temporarily suspending its share repurchase program.

Financial Statements
Beta

Key Highlights

  • 1Total operating revenue grew 20.7% year-over-year to $29.4 billion, significantly boosted by the launch and revenue generation of the IngenioRx PBM segment.
  • 2Net income decreased slightly by 1.8% to $1.5 billion, resulting in diluted EPS of $5.94, a 0.5% increase from the prior year, reflecting a lower share count.
  • 3The company completed the acquisition of Beacon Health Options, Inc. on February 28, 2020, expanding its reach in behavioral health services.
  • 4Operating cash flow increased substantially by 54.3% to $2.5 billion, primarily due to higher premium receipts and improved working capital management.
  • 5Medical membership grew by 3.2% to 42.1 million, with notable increases in Medicare Advantage and Medicaid, alongside growth in self-funded and fully-insured arrangements.
  • 6The reinstatement of the Health Insurance Provider (HIP) Fee for 2020 significantly impacted the effective tax rate, increasing it to 27.1% and contributing to higher income tax expense.
  • 7The company actively managed its financial flexibility in response to the COVID-19 pandemic, including borrowing under its credit facility, delaying tax payments, and temporarily suspending share repurchases.

Frequently Asked Questions

The primary driver for the 20.7% increase in total operating revenue to $29.4 billion was the launch of the IngenioRx pharmacy benefit manager (PBM) segment, which began generating product revenue in the second quarter of 2019 and contributed significantly in Q1 2020. Higher premium revenues from rate increases and membership growth in the Government Business segment also contributed to the overall revenue increase.

While the full impact was still unfolding, the company acknowledged that the COVID-19 pandemic could materially affect its business. For Q1 2020, the pandemic influenced operational dynamics (e.g., remote work), investment portfolio performance (leading to net realized losses on financial instruments), and prompted proactive measures like waiving cost-sharing for telehealth and COVID-19 treatments. The company also took steps to preserve liquidity, such as drawing on its credit facility and temporarily suspending share repurchases.

The acquisition of Beacon Health Options, Inc., completed on February 28, 2020, is a strategic move for Elevance Health to diversify into health services, particularly in the behavioral health sector. This acquisition aligns with the company's strategy to deliver integrated solutions and personalized care for individuals with complex and chronic conditions.

The company's investment portfolio experienced a net realized loss of $24 million on financial instruments in Q1 2020, compared to a net realized gain of $78 million in Q1 2019. This shift was primarily due to a decrease in net realized gains on equity securities, reflecting market volatility. Impairment losses recognized in income also increased to $57 million.